Adocia Sa · EURONEXT:ADOC
Adocia Sa — Investor Presentation (January 2025)
30 slides from Adocia Sa's investor presentation, January 2025
Slide 1: Corporate Presentation
Corporate Presentation January 2025
Slide 2: Forward-looking statements
Forward-looking statements ADOC This corporate presentation (the “Presentation”) has been prepared by ADOCIA S.A. (the “Company” and, together with its subsidiary, the “Group”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall m
Slide 3: Renewed management team
Renewed management team Olivier Soula Mathieu-William Gilbert PhD, MBA CEO Chief Financial Officer Co-founder Chief Operating Officer Leading a team of 80 experts, including 35 PhDs/MDs/PharmDs, based in Lyon, France 3 3
Slide 4: Diabetes and Obesity: Chronic pandemics due to peptide dysregulation
Diabetes and Obesity: Chronic pandemics due to peptide dysregulation Metabolic diseases Peptides dysregulation Peptide Due Insulin Treated Replacement Therapies Diabetes to Amylin by 537 million1 GLP-1 Efficient Obesity Glucagon Safe 1.9 billion2 … Delivery Challenges To address Peptides are ephemer
Slide 5: 4 proprietary platforms designed to unleash peptide-delivery in chronic diseases
4 proprietary platforms designed to unleash peptide-delivery in chronic diseases Peptides combinations BioChaperone® Improving efficacy with synergistic Mechanisms of Action Oral delivery of peptides AdOral® Avoiding injections and facilitating industrialization Long-acting delivery of peptides AdoG
Slide 6: Partnered catalysts
Demonstrated ability to invent, develop up to late stage and partner Preclinic Phase 1 Phase 2 Phase 3 Status / Upcoming milestones Partner Phase 3 readout H1 2025 BioChaperone® PARTNERED DIABETES $20m at Marketing Approval Lispro Double-Digit Royalties Exclusive negotiation right (€10m) OBESITY in
Slide 7: Upcoming major inflexion points potentially transforming value
Upcoming major inflexion points potentially transforming value BioChaperone® Amylin-GLP1 Combining next-gen obesity 1 products 2025 Formulation achieved on CagriSema and potential partnership M1Pram 2 Major partnership Licensing discussions w. Sanofi and launch of Ph. 2b in U.S. (T1D patients w. obe
Slide 8: BioChaperone Lispro
Diabetes BioChaperone® Lispro Ultra-Rapid Insulin for a tighter glycemic control Partnered with 8 8
Slide 9: BioChaperone Lispro, better efficacy vs. Humalog
BioChaperone® Lispro, better efficacy vs. Humalog Post-meal glycaemia in T1D AUC0-2h -61%* Better efficacy profile for fewer hyperglycemia and fewer hypoglycemia (“Faster-in” / “Faster-out”) Good tolerance Range of strengths (U100 & U200), adapted to miniature pumps and patients’ requirements Liquid
Slide 10: China Phase 3 clinical part terminated, filing under preparation
China Phase 3 clinical part terminated, filing under preparation Partnered with Tonghua Dongbao Licensed for development & commercialization for China and other Asian territories1: $10m upfront $5m milestone - 1st patient on the Phase 3 trial in China $10m milestone - Phase 3 Last Patient Last Visit
Slide 11: AdoShell Islets
Diabetes AdoShell® Islets To cure Type 1 Diabetes with islets transplantation without immunosuppression 11 11
Slide 12: Current islets transplantation faces challenges, drastically restricting its use
Current islets transplantation faces challenges, drastically restricting its use Immunosuppressants to avoid graft rejection is a high safety concern Cells from deceased donors are in short supply iPSCs under development present a risk of uncontrolled development AdoShell® aims to unlock the potenti
Slide 13: AdoShell Islets: the promise of cell therapy without immunosuppression
AdoShell® Islets: the promise of cell therapy without immunosuppression for all Type 1 Diabetes patients Immuno-isolation AdoShell® Islets Ab, T cells Large entities >10nm Allows insulin secretion in response of glycemic variation Protects cells from immune system Minimally invasive surgery (laparos
Slide 14: AdoShell Islets has demonstrated immuno-protection and functionality in vivo
AdoShell® Islets has demonstrated immuno-protection and functionality in vivo Transplantation of AdoShell containing allogenic islets in diabetic rat peritoneum at day 0 Sacrifice of control group at day 35 Explantation of the implant at day 132 First in Human in H2 2025 14 14
Slide 15: M1Pram
Diabetes & Obesity M1Pram Insulin + Amylin analogs combination Treating obesity in insulin-dependent people In exclusive negotiation with 15 15
Slide 16: Obesity in people with T1D is dramatically growing
Obesity in people with T1D is dramatically growing However, marketed obesity drugs are not approved in this population BMI3 in people with T1D1 Diabetes WEIGHT INSULIN In the U.S., people with T1D2 • Obesity (BMI≥30kg/m2): 40% • Overweight (BMI≥25kg/m2): 70% Obesity Adocia is developing the 1st obes
Slide 17: M1Pram: insulin and amylin combination to control glycemia and lose weight
M1Pram: insulin and amylin combination to control glycemia and lose weight Gold Standard Mealtime Insulin M1Pram = Insulin + Amylin Same number and time of injections Same glycemic control maintained Same risk of hypoglycemia Same local tolerance Weight loss Weight gain Equivalent weight loss to GLP
Slide 18: M1Pram reduces body weight in T1D with obesity, as much as best GLP1s in T2D
M1Pram reduces body weight in T1D with obesity, as much as best GLP1s in T2D Marketed obesity drugs in T2D taking insulin (basal) M1Pram in people with T1D BW Change from baseline at W16 Insulin lispro (Humalog®) -0.57 kg (-0.74%), N=9 • Semaglutide1 (Ozempic) - 4.55 kg vs. - 1.08 kg M1Pram -5.56 kg
Slide 19: BioChaperone CagriSema
Diabetes & Obesity BioChaperone® CagriSema Combining peptides for greater and better weight loss 19 19
Slide 20: BioChaperone: improving obesity drugs through peptide co-formulation
BioChaperone®: improving obesity drugs through peptide co-formulation CagriSema 4 double-chamber pens 1 multi-use pen + /month /month Single-use double-chamber pen • Novo Nordisk Cagrilintide Semaglutide • Phase 3: obesity, diabetes • -22% weight loss/year • Sales forecast (2030)1: ~$16 bn BioChaper
Slide 21: AdOral
Diabetes & Obesity AdOral® Oral delivery of peptides to avoid injections and to facilitate industrialization 21 21
Slide 22: AdOral, a proprietary oral delivery technology for peptides
AdOral®, a proprietary oral delivery technology for peptides 4. The permeation 1. Gastro-resistant galenic Peptide PE enhancer (PE) works by PI solid form Proteases increasing paracellular absorption across the intestinal epithelium Closed TJ 2. Solid form dissolves at neutral pH Open Tight Junction
Slide 23: AdOral has been validated on semaglutide with improved bioavailability in animal
AdOral® has been validated on semaglutide and shows significantly improved bioavailability in animal Median Semaglutide 14mg PK Profile (N=10) Reduced API quantity to deliver the therapeutic dose Manufacturing 2.5-fold higher Industrial advantages vs. sterile cost median than injectables Rybelsus®
Slide 24: AdoGel
Diabetes & Obesity AdoGel® Long-acting formulation to reduce the number of injections 24 24
Slide 25: AdoGel Sema, a once-monthly formulation of semaglutide
AdoGel® Sema, a once-monthly formulation of semaglutide AdoGel® Sema Injectable Pharmacokinetic in rats + + • No burst Polymer 1 Polymer 2 Semaglutide • Low Cmax Gel Cross-linking reaction + Emulsification + formation between polymers 1 and 2 Polymer 1 Polymer 2 Drug Crosslinked hydrogel Compatible
Slide 26: AdoGel, an injectable hydrogel for sustained release of peptides
AdoGel®, an injectable hydrogel for sustained release of peptides From weekly to monthly or quarterly injections: Next steps: Proof of Concept on AdoGel® Sema Overcomes the need for repeated drug administration on big animals ongoing Avoids an initial concentration peak IP: Patented 2045 Adocia inte
Slide 27: Financials & Conclusions
Financials & Conclusions 27 27
Slide 28: Key Financials
Key Financials • Cash position (2024, Sept. 30): €9,3 million Shareholder ownership - Cash runway: Q3 20251 October 30, 2024 - $10m milestone payment to be received in Q2 2025 • Indebtedness: €5.2m (state-guaranteed loan maturing Free float Aug. 2026) 69,6% Soula Family & Employees • 75% cash burn d
Slide 29: Adocia at a glance
Adocia at a glance 1 Mission: to develop innovative peptide formulations for diabetes and obesity treatment Business model: Licensing-out our products and technologies after proof of concept 2 2 partners: Tonghua Dongbao (BC Lispro, licensed for Asia), Sanofi (exclusive option on M1Pram) 3 Assets: 3
Slide 30: Thank you for your kind interest
Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com